FREEDOM OF ACCESS TO MEDICINES NEWSLETTER #12
June 29, 2011
Day #2 of FDA Avastin Hearing!
INSIDE THE HEARING
Today Genentech/Roche is presenting their data and the case why Avastin is working to extend the lives of those patients with Metastatic Breast Cancer. They are stating which points they agree with and disagree on to the FDA panel. We will bring you a recap on the day's events in the next newsletter and on our Hearing web page: www.fameds.org/hearing
AVASTIN IN THE MEDIA
For the Rally, FAMEDS printed and purchased many flyers, signs, banners, t-shirts, and rented a shuttle to Capitol Hill among other costs. Please consider helping and giving a tax-deductible donation of any amount: www.fameds.org/makeadonation
We greatly appreciate our supporters!